Fuse Biotherapeutics is a developer of immunotherapies for cancer patients. Its therapeutics are focused on IL-18, a hormone-like protein that is released in response to danger, such as cancer, to stimulate the immune system. The protein promotes the survival of immune cells that kill tumors and oppose late-stage immune exhaustion.